FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4255263208> ?p ?o ?g. }

• W4255263208 abstract "The results from controlled clinical trials investigating the efficacy of azathioprine and 6-mercaptopurine for the treatment of active Crohn's disease have been conflicting and controversial. An updated meta-analysis was performed to assess the effectiveness of these drugs for the induction of remission in active Crohn's disease.The primary objective was to determine the efficacy and safety of azathioprine and 6-mercaptopurine for induction of remission in active Crohn's disease.A literature search for relevant studies (inception to June 13, 2012) was performed using MEDLINE, EMBASE and the Cochrane Library. Review articles and conference proceedings were also searched to identify additional studies.Randomized controlled trials (RCTs) of oral azathioprine or 6-mercaptopurine compared to placebo or active therapy involving adult patients with active Crohn's disease were selected for inclusion.Data were extracted by two independent observers based on the intention-to-treat principle. Outcomes of interest included: clinical remission, clinical improvement, fistula improvement or healing, steroid sparing, adverse events, withdrawals due to adverse events and serious adverse events. We calculated the pooled relative risk (RR) and 95% confidence intervals (95% CI) for each outcome. The methodological quality of included studies was evaluated using the Cochrane risk of bias tool. The overall quality of the evidence supporting each outcome was assessed using the GRADE criteria.Thirteen RCTs (n = 1211 patients) of azathioprine and 6-mercaptopurine therapy in adult patients were identified: nine included placebo comparators and six included active comparators. The majority of included studies were rated as low risk of bias. There was no statistically significant difference in clinical remission rates between azathioprine or 6-mercaptopurine and placebo. Forty-eight per cent (95/197) of patients receiving antimetabolites achieved remission compared to 37% (68/183) of placebo patients (5 studies, 380 patients; RR 1.23, 95% CI 0.97 to 1.55). There was no statistically significant difference in clinical improvement rates between azathioprine or 6-mercaptopurine and placebo. Forty-eight per cent (107/225) of patients receiving antimetabolites achieved clinical improvement or remission compared to 36% (75/209) of placebo patients (8 studies, 434 patients; RR 1.26, 95% CI 0.98 to 1.62). There was a statistically significant difference in steroid sparing (defined as prednisone dose < 10 mg/day while maintaining remission) between azathioprine and placebo. Sixty-four per cent (47/163) of azathioprine patients were able to reduce their prednisone dose to < 10 mg/day compared to 46% (32/70) of placebo patients (RR 1.34, 95% CI 1.02 to 1.77). GRADE analyses rated the overall quality of the evidence for the outcomes clinical remission, clinical improvement and steroid sparing as moderate due to sparse data. There was no statistically significant difference in withdrawals due to adverse events or serious adverse events between antimetabolites and placebo. Ten percent of patients in the antimetabolite group withdrew due to adverse events compared to 5% of placebo patients (8 studies, 510 patients; RR 1.70, 95% CI 0.94 to 3.08). Serious adverse events were reported in 14% of patients receiving azathioprine compared to 4% of placebo patients (2 studies, 216 patients; RR 2.57, 95% CI 0.92 to 7.13). Common adverse events reported in the placebo controlled studies included: allergic reactions. leukopenia, pancreatitis and nausea. Azathioprine was significantly inferior to infliximab for induction of steroid-free clinical remission. Thirty per cent (51/170) of azathioprine patients achieved steroid-free remission compared to 44% (75/169) of infliximab patients (1 study, 339 patients; RR 0.68, 95% CI 0.51 to 0.90). The combination of azathioprine and infliximab was significantly superior to infliximab alone for induction of steroid-free clinical remission. Sixty per cent (116/194) of patients in the combined azathioprine and infliximab group achieved steroid-free remission compared to 48% (91/189) of infliximab patients (2 studies, 383 patients; RR 1.23, 95% CI 1.02 to 1.47). Azathioprine or 6-mercaptopurine therapy was found to be no better at inducing steroid free clinical remission compared to methotrexate (RR 1.13, 95% CI 0.85 to 1.49) and 5-aminosalicylate or sulfasalazine (RR 1.24, 95% CI 0.80 to 1.91). There were no statistically significant differences in withdrawals due to adverse events between azathioprine or 6-mercaptopurine and methotrexate (RR 0.78, 95% CI 0.23 to 2.71); between azathioprine or 6-mercaptopurine and 5-aminosalicylate or sulfasalazine (RR 0.98, 95% CI 0.38 to 2.54); between azathioprine and infliximab (RR 1.47, 95% CI 0.96 to 2.23); or between the combination of azathioprine and infliximab and infliximab (RR 1.16, 95% CI 0.75 to 1.80). Common adverse events in the active comparator trials included nausea, abdominal pain, pyrexia and headache.Azathioprine and 6-mercaptopurine offer no advantage over placebo for induction of remission or clinical improvement in active Crohn's disease. Antimetaboilte therapy may allow patients to reduce steroid consumption. Adverse events were more common in patients receiving antimetabolites although differences with placebo were not statistically significant. Azathioprine therapy is inferior to infliximab for induction of steroid-free remission. However, the combination of azathioprine and infliximab was superior to infliximab alone for induction of steroid-free remission." @default.
• W4255263208 created "2022-05-12" @default.
• W4255263208 creator A5036883744 @default.
• W4255263208 creator A5065846093 @default.
• W4255263208 creator A5072796506 @default.
• W4255263208 date "2013-04-30" @default.
• W4255263208 modified "2023-09-26" @default.
• W4255263208 title "Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease" @default.
• W4255263208 cites W1422703799 @default.
• W4255263208 cites W1517931144 @default.
• W4255263208 cites W1528563142 @default.
• W4255263208 cites W1754807032 @default.
• W4255263208 cites W1761355724 @default.
• W4255263208 cites W18063648 @default.
• W4255263208 cites W1883339282 @default.
• W4255263208 cites W1948846488 @default.
• W4255263208 cites W1961133398 @default.
• W4255263208 cites W1963887927 @default.
• W4255263208 cites W1965215103 @default.
• W4255263208 cites W1965544328 @default.
• W4255263208 cites W1967490229 @default.
• W4255263208 cites W1968287266 @default.
• W4255263208 cites W1968809716 @default.
• W4255263208 cites W1971740020 @default.
• W4255263208 cites W1975645772 @default.
• W4255263208 cites W1979198688 @default.
• W4255263208 cites W1980692490 @default.
• W4255263208 cites W2007498173 @default.
• W4255263208 cites W2009285886 @default.
• W4255263208 cites W2009643606 @default.
• W4255263208 cites W2011377010 @default.
• W4255263208 cites W2012274022 @default.
• W4255263208 cites W2016321388 @default.
• W4255263208 cites W2024293518 @default.
• W4255263208 cites W2025343624 @default.
• W4255263208 cites W2029841402 @default.
• W4255263208 cites W2032313414 @default.
• W4255263208 cites W2032965564 @default.
• W4255263208 cites W2036248853 @default.
• W4255263208 cites W2037707239 @default.
• W4255263208 cites W2043258441 @default.
• W4255263208 cites W2043527682 @default.
• W4255263208 cites W2045123507 @default.
• W4255263208 cites W2060643376 @default.
• W4255263208 cites W2062369130 @default.
• W4255263208 cites W2062913921 @default.
• W4255263208 cites W2072179061 @default.
• W4255263208 cites W2076658981 @default.
• W4255263208 cites W2082975276 @default.
• W4255263208 cites W2088315857 @default.
• W4255263208 cites W2088513474 @default.
• W4255263208 cites W2090307291 @default.
• W4255263208 cites W2090549398 @default.
• W4255263208 cites W2093253461 @default.
• W4255263208 cites W2095027842 @default.
• W4255263208 cites W2099342952 @default.
• W4255263208 cites W2112907719 @default.
• W4255263208 cites W2117212747 @default.
• W4255263208 cites W2123799332 @default.
• W4255263208 cites W2125435699 @default.
• W4255263208 cites W2126807394 @default.
• W4255263208 cites W2127664523 @default.
• W4255263208 cites W2135958206 @default.
• W4255263208 cites W2149298762 @default.
• W4255263208 cites W2151525708 @default.
• W4255263208 cites W2152381563 @default.
• W4255263208 cites W2165010366 @default.
• W4255263208 cites W2171603465 @default.
• W4255263208 cites W2171978407 @default.
• W4255263208 cites W2314055620 @default.
• W4255263208 cites W4237602455 @default.
• W4255263208 cites W4250634492 @default.
• W4255263208 cites W639061854 @default.
• W4255263208 cites W83929735 @default.
• W4255263208 doi "https://doi.org/10.1002/14651858.cd000545.pub4" @default.
• W4255263208 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23633304" @default.
• W4255263208 hasPublicationYear "2013" @default.
• W4255263208 type Work @default.
• W4255263208 citedByCount "54" @default.
• W4255263208 countsByYear W42552632082013 @default.
• W4255263208 countsByYear W42552632082014 @default.
• W4255263208 countsByYear W42552632082015 @default.
• W4255263208 countsByYear W42552632082016 @default.
• W4255263208 countsByYear W42552632082017 @default.
• W4255263208 countsByYear W42552632082018 @default.
• W4255263208 countsByYear W42552632082019 @default.
• W4255263208 countsByYear W42552632082020 @default.
• W4255263208 countsByYear W42552632082021 @default.
• W4255263208 countsByYear W42552632082022 @default.
• W4255263208 crossrefType "reference-entry" @default.
• W4255263208 hasAuthorship W4255263208A5036883744 @default.
• W4255263208 hasAuthorship W4255263208A5065846093 @default.
• W4255263208 hasAuthorship W4255263208A5072796506 @default.
• W4255263208 hasConcept C126322002 @default.
• W4255263208 hasConcept C142724271 @default.
• W4255263208 hasConcept C168563851 @default.
• W4255263208 hasConcept C197934379 @default.
• W4255263208 hasConcept C204787440 @default.
• W4255263208 hasConcept C27081682 @default.
• W4255263208 hasConcept C2776478404 @default.

• next